Protective shield from Omicron: the third dose will be taken from next year, there is an initial agreement on vaccinating such individuals

Parikshit Nirbhay, Amar Ujala, New Delhi.

Published by: Yogesh Sahu
Updated Saturday, 18 December 2021 06:32 AM IST

Summary

An agreement has been reached between the National Technical Immunization Advisory Committee and the Empowered Group of the Central Government on corona vaccination for overdose. However, even after this extra dose is approved, there are still many obstacles to overcome.

Listen to the news

A third additional dose of the corona vaccine is being discussed. To prevent the appearance of Omicron, its vaccines have also been launched abroad, but even in India, it has been decided to give additional doses to health workers and high-risk populations from next year, which has not yet been officially announced.

Even after this decision many obstacles need to be overcome. That is why the government is waiting everywhere. The omicron variant is waiting to be isolated in one step. On the other hand, the results of the initiated studies on Kovishield and Kovoxin‌ have not even come yet.

A senior physician affiliated with the National Technical Immunization Advisory Committee said that almost all experts agreed to give an additional dose of the vaccine, but now we can not allow it because we have nothing about a third dose.

The Kovshield vaccine has been tested in the UK but has not yet been tested in India. An additional dose for covaxin is also working, but it is important to isolate the omicran variant for that. This work is being done by scientists at the National Institute of Virology (NIV) in Pune.

This process takes two to three weeks. In such a situation, experts are still waiting for its news from NIV. The senior doctor said that there are about 40 crore health workers and high risk population in the country and they have been selected for additional doses.

The rules and the decision on the approval of vaccines are different

An empowerment team official said that formulating an overdose regimen and approving the vaccine were two different things. The National Technical Immunization Advisory Committee and the Immunization Committee chaired by Dr. VK Paul are working to formulate the rules.

Infected 7447 people in the last 24 hours
7447 people were infected in a single day in the country. 391 people died. At the same time, 7886 patients were discharged. Active cases 86,415.

WHO approval for Kovacs emergency use

The World Health Organization has approved the US company Novavox vaccine Kovavax, which is manufactured at the Serum Institute of India for emergency use on corona patients. In addition, the vaccine may be included in the United Nations World Vaccine Supply Program, which distributes the vaccine to poor countries around the world.

This vaccine, popularly known as Kovavax TM, is the ninth vaccine to receive the WHO green signal. With this decision, even those who are now vaccinated with KovavaxTM will be able to travel to countries that are exempt from traveling only to WHO-certified vaccines. This vaccine is very easy to maintain and can be kept for a long time only with the help of refrigerator. With this feature, this vaccine will provide great relief to poor countries.

Range

A third additional dose of the corona vaccine is being discussed. To prevent the appearance of Omicron, its vaccines have also been launched abroad, but even in India, it has been decided to give additional doses to health workers and high-risk populations from next year, which has not yet been officially announced.

Even after this decision many obstacles have to be overcome. That is why the government is waiting everywhere. The omicron variant is waiting to be isolated in one step. On the other hand, the results of the initiated studies on Kovishield and Kovoxin‌ have not even come yet.

A senior physician affiliated with the National Technical Immunization Advisory Committee said that almost all experts agreed to give an additional dose of the vaccine, but now we can not allow it because we have nothing about a third dose.

The Kovshield vaccine has been tested in the UK but has not yet been tested in India. An additional dose for covaxin is also working, but it is important to isolate the omicran variant for that. This work is being done by scientists at the National Institute of Virology (NIV) in Pune.

This process takes two to three weeks. In such a situation, experts are still waiting for its news from NIV. The senior doctor said that there are about 40 crore health workers and high risk population in the country and they have been selected for additional doses.

.

[ad_2]

Source link

Leave a Comment